Fosun Pharma three quarterly revenue 3.329 billion yuan year-on-year increase of 19%

Fosun Medicine (600196) SH) today released the 2010 Quarterly report, the first three quarter of this year to achieve business income of 3.329 billion yuan, an increase of 19% To achieve the net profit attributable to the parent company 738 million yuan, of which the operating net profit is 380 million yuan, excluding the factor of dilution of the listed shares of the Chinese medicines Holding (01099.HK), the operating net profit increases 28%, achieves the income of 0.39 yuan per share.　　The growth of the company's operating net profit mainly stems from the continuous improvement of the core pharmaceutical manufacturing and pharmaceutical commercial enterprises. 2010 years ago Three quarters, the company's core pharmaceutical companies pharmaceutical drugs, all the medicine, Hubei new source of sales revenue are fast growth, increase to more than 25%.　　In the areas of diabetes, liver disease, malaria treatment and other diseases, the main products continue to maintain a leading position in the market segments. In the pharmaceutical business, Fosun Pharmaceutical Corporation, the Chinese Medicine company, continues to strengthen its position as a leading enterprise in China's pharmaceutical distribution industry, sales are expected to exceed 100 billion yuan this year, while in the retail business, Fosun Pharmaceutical subsidiary of the main pharmaceutical retail Enterprises Forte Pharmacy, Golden Elephant Pharmacy, etc. continue to lead the region's pharmaceutical retail industry,　　The number of stores and profitability are in the leading position in the regional market, and the integration has been completed. Which, in mid-October, Fosun Medicine spent 120 million yuan to increase capital of Beijing gold Elephant Pharmacy, so that the proportion of the shareholding rose to 76.3%, thereby gaining absolute control; contact to the beginning of this year, Fosun's largest pharmacy officially renamed as the Complex Beauty pharmacy, Fosun Medicine in the Beijing-Shanghai retail chain has been integrated,　　Since then, the situation of North-south echoes has been formed. In addition to the investment in pharmaceuticals and the business sector, equity investment has always been a forte in the field of Fosun Medicine, in the third quarter of this year, Fosun Medicine held the gene chip diagnostics enterprise---------------------------------------- Dheere Medical. The above series of investments means Fosun's medicine has begun to cloth its pieces in the area of medical services and diagnostics.